Back to results
US 2023/0046656 A1Published application
Crebbp related cancer therapy
AssigneeEpizyme, Inc.
InventorsAlexandra Grassian, Scott Ribich, Jesse Smith, Darren Martin Harvey
Life of this patent
Estimating the term…
Abstract
The present disclosure provides novel cancer therapies. The treatment of cancers harboring EP300 mutations with CREBBP inhibition therapy is described.
Claims30
A method of treating cancer comprising a step of:
- inhibiting CREBBP in a subject in need thereof, wherein the subject has or is diagnosed with a cancer having at least one mutation in EP300 that is a frame shift mutation, a splice variant, a missense mutation, a nonsense mutation, an insertion, a deletion, or a combination thereof.
(canceled)
4-6. (canceled)
(canceled)
(canceled)
17-20. (canceled)
(canceled)
(canceled)
29-30. (canceled)
34-68. (canceled)
A method for identifying a CREBBP antagonist, the method comprising the steps of:
- contacting a system comprising at least CREBBP, a CREBBP substrate, and an acetyl donor with a candidate CREBBP antagonist;
- and
- detecting acetylation of the CREBBP substrate.
70-71. (canceled)
Dependencies are inferred from the claim text.